2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Profiling, Treatment Considerations, Drug Development, Drug-Drug Interactions, Supportive Care, Biological Therapies, Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Immunology, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, ALL, Aggressive Lymphoma, Research, Fundamental Science, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pregnant
PAPER

1328 Effectiveness of inferior vena cava filter in lower extremity free floating thrombi

Katherine Li, Alexa Loncharich, MD2, Ryan Dingle3, Nehemias Guevara Rodriguez, MD4, Sarah Addison, MD, BS5, Patrick Geraghty, MD6, Amber Afzal, MD, MSCI7, Kristen Marie Sanfilippo, MD, MPHS8
1 Washington University In Saint Louis, Saint Louis, Missouri, United States
2 Washington University In Saint Louis, Saint Louis, Missouri, United States
3 Washington University In Saint Louis, Saint Louis, Missouri, United States
4 SSM Health Saint Louis University, Saint Louis, Missouri, United States
5 Washington University In Saint Louis, Saint Louis, Missouri, United States
6 Washington University In Saint Louis, Saint Louis, Missouri, United States
7 Washington University In Saint Louis, Saint Louis, Missouri, United States
8 Veterans Administration Medical Center Saint Louis, Saint Louis, Missouri, United States, Washington University In Saint Louis, Saint Louis, Missouri, United States

Introduction:

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is associated with significant morbidity as well as mortality with a high case-fatality rate of 9.4% and 15.1% in the first month following initial DVT and PE, respectively.  Free-floating thrombus (FFT) refers to a type of thrombus characterized by the presence of a segment non-adherent to the vessel wall. The presence of a non-adherent segment raises clinical concern for embolization risk with prior retrospective studies reporting a 3.3% to 60% incidence of secondary PE for FFT. The literature provides conflicting results on risk of embolization in FFT compared to occlusive thrombi. Given the paucity of data, there is little guidance on optimal management of FTT. In this retrospective study, we aimed to determine the effectiveness of inferior vena cava (IVC) filters in prevention of a secondary PE in patients treated with anticoagulant therapy in a large cohort of patients with lower extremity FFT.

Materials and Methods: 

Natural Language Processing was used to identify patients with FFT in a deep vein of the lower extremity on venous duplex ultrasound that was obtained at our institution between January 1, 2018 and October 1, 2023. Identification as FFT required description using any of the following terms: “loosely attached,” “loosely adherent,” “partially attached,” “partially adherent,” “mobile” or “free floating”.  Eligible lower extremity locations include DVT occurring in the inferior vena cava or in the proximal or distal lower extremities. FFT managed with anticoagulation with or without the insertion of an IVC filter were included in this analysis.  Eligible initial anticoagulant therapy included: unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), fondaparinux, and direct oral anticoagulation (DOAC). The primary outcome was secondary PE, defined as a new PE occurring within 90 days after FFT diagnosis. All data were stored using REDCap. Data were processed using Python version 3.12.13. The study and study personnel received IRB approval from Washington University prior to any study activity. 

Results:

Of 481 patients with lower-extremity or inferior vena cava FFT, we identified 402 patients managed with anticoagulant (AC) therapy (68.2% therapeutic UFH/LMWH, 29.1% DOAC, and 2.7% prophylactic dose UFH/LMWH). Of these, 364 were managed with AC alone and 38 received an IVC filter in addition to AC therapy.  Clinical characteristics, including age, body mass index, gender, race, and previous VTE history, were not significantly different between these cohorts. The patients that received an IVC filter were more likely to have  major surgery within 90 days prior to the event (52.6% vs 20.9%, p<0.001), concurrent PE at the time of FFT diagnosis (55.3% vs 33.2%, p=0.012), and receive parenteral therapeutic AC with UFH or LMWH (94.7% vs 65.4%, p<0.001) compared to the AC monotherapy cohort.  

Overall, 21 patients (5.3%) developed a secondary PE within 90 days of FFT. 2.7% developed a secondary PE in the AC+IVC filter cohort compared to 5.5% in the AC only cohort (Odds Ratio [OR] 0.48, 95% CI 0.06–3.64). There was no difference in secondary PE rates after adjusting for AC type, DVT location (proximal vs distal) and provoking factors (e.g., recent major surgery) (aOR 0.78, 95% CI 0.14 – 4.47).

Conclusion:

Overall, we observed an incidence of 5.3% of secondary PE following diagnosis of lower extremity FFT.  This is lower than reported in many of the prior publications. The placement of an IVC filter did not lead to a significant difference in development of a secondary PE even after adjusting for AC treatment type and location of DVT. Further work is indicated to determine factors predictive of secondary PE.

Katherine Li: No relevant conflicts of interest to declare.